|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs).A total of 146 coronary heart disease patients of Han ethnicity, on a clopidogrel regimen, were enrolled.
|
27488401 |
2016 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We determined the association of CYP2C19 loss-of-function (*2) and gain-of-function (*17) allele status with platelet reactivity in 118 stented patients on DAPT ≥2 weeks and in 143 patients with stable coronary artery disease on aspirin therapy alone.
|
21392617 |
2011 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among 20 CAD samples, 13 of 20 (65%) showed CYP2C19 gene over expression in CAD patients and all controls showed normal expression.
|
27915083 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19*2 genotype is associated with an increased risk of definite ST following coronary stent placement among Chinese patients with coronary artery disease receiving clopidogrel.
|
22118006 |
2011 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
|
30403317 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variation in the gene encoding CYP2C19 in patients with stable CAD contributes to reduced exposure to clopidogrel's active metabolite and a corresponding reduction in P2Y(12) inhibition, but has no significant influence on the response to prasugrel.
|
19429918 |
2009 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data from six clinical studies demonstrated that carriers of the CYP2C19*17 variant had a marked protection against recurrent cardiovascular events in patients with coronary artery disease compared with non-carriers, as measured by a 16% decrease in the incidence of MACE (10.0% vs. 11.9%; OR, 0.82; 95% CI, 0.72-0.94; P = 0.005).
|
22123356 |
2012 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.
|
21693476 |
2012 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was carried out to analyze the contributions of CYP2C19 polymorphisms and risk factors to the various clopidogrel responses in Chinese patients with stable CAD after PCI.
|
24608794 |
2014 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
|
26071277 |
2015 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, CYP2C19*3 single-nucleotide polymorphisms is an independent risk factor of clopidogrel resistance in Korean subjects with coronary artery disease.
|
19576320 |
2009 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
|
25891840 |
2015 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The platelet aggregation induced by 20 µmol/l adenosine diphosphate (ADP) and CYP2C19 single-nucleotide polymorphisms (*2 and *3) was determined in patients with coronary artery disease (CAD) who were taking aspirin alone (n = 21), aspirin plus clopidogrel (n = 97), or aspirin plus ticlopidine (n = 47).
|
21178986 |
2011 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the impact of CYP2C19 genotype on clinical outcome in coronary artery disease (CAD) patients with or without diabetes mellitus (DM).
|
24821368 |
2014 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.
|
28687336 |
2017 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, carrier status for LOF CYP2C19 is associated with an increased risk of adverse clinical events in patients with coronary artery disease on clopidogrel therapy despite differences in clinical significance according to ethnicity.
|
22591668 |
2012 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eligibility criteria for selecting studies Original full length reports assessing the cumulative incidence of major adverse cardiovascular events or stent thrombosis over a follow-up period of at least a month in association with carrier status for the loss of function or gain of function CYP2C19 allele in adult patients with coronary artery disease and a clinical presentation of acute coronary syndrome or stable angina pectoris who were taking clopidogrel.
|
21816733 |
2011 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
|
24402637 |
2014 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The effect of CYP2C19 gene polymorphism on clinical outcomes of patients with coronary artery disease (CAD) treated with clopidogrel remains controversial.
|
29257922 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C or CYP2J2 have a pathologic impact on coronary artery diseases.
|
21476972 |
2011 |
|
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, the number and the type of coronary disease (thrombotic, fibrotic or both) did not differ between patients with different CYP2C19 enzyme activity.
|
28473221 |
2017 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of CYP2C19 reduced-function allele constituted 131 (65%) of 202 CAD patients.
|
21862109 |
2011 |
|
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 (*1, *2, *3, *4, *5, *6, *7, *8, *17) genotyping was performed in patients with coronary artery disease treated with ticagrelor (180-mg load, 90 mg BID) (n=92) or clopidogrel (600-mg load, 75 mg/d) (n=82).
|
21079055 |
2010 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19*3 polymorphism and CAD were synergistically and significantly associated in Chinese Uighur patients.
|
20460345 |
2010 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
|
20845077 |
2011 |